文献速递肺外科

肺叶切除术与质子治疗用于I期非小细胞肺癌的比较

Lobectomy versus proton therapy for stage I non-small cell lung cancer.
PubMed 文献 · J Thorac Cardiovasc Surg · 2023-08-23

该回顾性研究纳入275例组织学确诊的临床I期非小细胞肺癌患者(肺叶切除术206例、质子治疗69例),经倾向性评分匹配后各59例,中位随访50个月。匹配队列中两组总生存、病因特异性生存、无复发生存、局部控制、区域淋巴结控制及远处控制均无显著差异。作者结论为两种治疗方式在生存和疾病控制方面无差异,但存在未测量混杂因素可能,需随机对照试验进一步比较。

要点

  • 匹配队列中肺叶切除术与质子治疗的5年总生存率分别为85.8%和79.1%,无显著差异(P=.26)。
  • 匹配队列中两组无复发生存率分别为82.3%和77.8%(P=.53),局部控制率分别为92.1%和96.6%(P=.41)。
  • 作者结论为两种治疗方式在生存和疾病控制方面无差异,但存在未测量混杂因素可能,需随机对照试验。

核心结论

  • 在组织学确诊的临床I期非小细胞肺癌患者中,肺叶切除术与质子治疗在生存和疾病控制方面无差异。
  • 尽管有此发现,仍存在未测量混杂因素的可能性,需要随机对照试验来更好地比较这两种治疗方式。

研究设计与样本

  • 回顾性分析本院2013年7月至2020年12月收治的275例组织学确诊的临床I期非小细胞肺癌患者,其中肺叶切除术206例、质子治疗69例。
  • 采用倾向性评分匹配以减少两组间的选择偏倚,匹配后队列为肺叶切除术59例和质子治疗59例,中位随访50个月。
  • 终点包括总生存、病因特异性生存、无复发生存、局部控制、区域淋巴结控制和远处控制。

主要发现

  • 匹配队列中,总生存(P=.26)、病因特异性生存(P=.33)、无复发生存(P=.53)、局部控制(P=.41)、区域淋巴结控制(P=.98)和远处控制(P=.31)均无显著差异。
  • 肺叶切除术组与质子治疗组的5年总生存率分别为85.8%和79.1%,无复发生存率分别为82.3%和77.8%,局部控制率分别为92.1%和96.6%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出尽管有此发现,仍存在未测量混杂因素的可能性。
  • 原文指出需要随机对照试验来更好地比较这两种治疗方式。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Lobectomy is the standard treatment for patients with early-stage non-small cell lung cancer (NSCLC). In recent years, an increasing number of patients with lung cancer have been treated using proton therapy (PT). We conducted a propensity score-matched analysis to compare the treatment outcomes of these 2 modalities. METHODS: We retrospectively reviewed data from 275 patients with histologically confirmed clinical stage I NSCLC who underwent lobectomy (n = 206) or PT (n = 69) at our institution from July 2013 to December 2020. The end points were overall survival (OS), cause-specific survival, recurrence-free survival (RFS), local control, regional lymph node control, and distant control. Propensity score matching was performed to reduce selection bias in the 2 groups. RESULTS: The matched cohort consisted of 59 patients who underwent lobectomy and 59 patients who underwent PT with a median follow-up period of 50 months. There were no significant differences in OS (P = .26), cause-specific survival (P = .33), RFS (P = .53), local control (P = .41), regional lymph node control (P = .98), and distant control (P = .31). In the lobectomy and PT groups, the 5-year OS rate was 85.8% and 79.1%, respectively, the RFS rate was 82.3% and 77.8%, and the local control rate was 92.1% and 96.6%. CONCLUSIONS: We found no difference in survival or disease control between lobectomy and PT in patients with histologically confirmed clinical stage I NSCLC. Despite these findings, the potential for unmeasured confounding factors remains, and randomized control trials are needed to better compare these treatment modalities.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Sakane T, Nakajima K, Iwata H, et al. Lobectomy versus proton therapy for stage I non-small cell lung cancer. J Thorac Cardiovasc Surg. 2023. PMID: 37625619. doi:10.1016/j.jtcvs.2023.08.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。